The budget allocation for the Ministry of Ayush has been increased to Rs 3,992.90 crore for 2025-26 from Rs 3,497.64 crore (revised estimates) in 2024-25, a 14.15 per cent hike.
The National Medicinal Plants Board has been allocated Rs 18.59 crore while the Pharmacopoeia Commission for Indian Medicine and Homoeopathy (PCIM&H) has been allocated Rs 21.96 crore.
The National Medicinal Plants Board undertakes promotional and contractual farming schemes to encourage in-situ conservation and ex-situ cultivation of medicinal plants for providing raw materials of assured quality for manufacturing of ASU&H (Ayurveda, Siddha, Unani and Homeopathy) medicines.
The Pharmacopoeia Commission for Indian Medicine and Homoeopathy is a subordinate office under the Ministry of Ayush. It is an appellate authority for testing of all Ayush drugs in India. It also sets the standards for all Ayush drugs that are published in the form of pharmacopoeias.
The autonomous bodies have been allocated Rs 1,965.80 crore, of which Central Council for Research in Ayurvedic Sciences has been given Rs 457.20 crore, Central Council for Research in Homeopathy has been given Rs 165 crore, Central Council for Research in Unani Medicine has been given Rs 214.50 crore and All India Institute of Ayurveda has been given Rs 251.20 crore.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app